Tributary Capital Management LLC Has $346,000 Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Tributary Capital Management LLC lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 30.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,810 shares of the specialty pharmaceutical company’s stock after selling 1,230 shares during the quarter. Tributary Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $346,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of JAZZ. EverSource Wealth Advisors LLC raised its holdings in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the period. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the period. GAMMA Investing LLC lifted its position in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 121 shares in the last quarter. Itau Unibanco Holding S.A. boosted its stake in Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares during the period. Finally, Venturi Wealth Management LLC increased its holdings in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on JAZZ. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. TD Cowen decreased their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. This represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,253 shares of company stock valued at $1,001,434 in the last ninety days. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $122.04 on Friday. The company has a market capitalization of $7.38 billion, a price-to-earnings ratio of 17.19, a PEG ratio of 0.87 and a beta of 0.56. The stock’s 50 day moving average is $122.37 and its 200-day moving average is $115.36. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.